- Home
- LXRX vs MYGN Comparison
LXRX vs MYGN Comparison
Compare LXRX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXRX
- MYGN
- Stock Information
- Founded
- LXRX 1995
- MYGN 1991
- Country
- LXRX United States
- MYGN United States
- Employees
- LXRX N/A
- MYGN N/A
- Industry
- LXRX Biotechnology: Pharmaceutical Preparations
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- LXRX Health Care
- MYGN Health Care
- Exchange
- LXRX Nasdaq
- MYGN Nasdaq
- Market Cap
- LXRX 541.5M
- MYGN 625.5M
- IPO Year
- LXRX 2000
- MYGN 1995
- Fundamental
- Price
- LXRX $1.34
- MYGN $7.40
- Analyst Decision
- LXRX Buy
- MYGN Hold
- Analyst Count
- LXRX 5
- MYGN 14
- Target Price
- LXRX $3.23
- MYGN $13.23
- AVG Volume (30 Days)
- LXRX 2.3M
- MYGN 1.2M
- Earning Date
- LXRX 11-06-2025
- MYGN 11-03-2025
- Dividend Yield
- LXRX N/A
- MYGN N/A
- EPS Growth
- LXRX N/A
- MYGN N/A
- EPS
- LXRX N/A
- MYGN N/A
- Revenue
- LXRX $70,864,000.00
- MYGN $825,300,000.00
- Revenue This Year
- LXRX $66.55
- MYGN $0.06
- Revenue Next Year
- LXRX N/A
- MYGN $5.68
- P/E Ratio
- LXRX N/A
- MYGN N/A
- Revenue Growth
- LXRX 1255.21
- MYGN 0.21
- 52 Week Low
- LXRX $0.28
- MYGN $3.76
- 52 Week High
- LXRX $1.66
- MYGN $16.83
- Technical
- Relative Strength Index (RSI)
- LXRX 44.82
- MYGN 55.39
- Support Level
- LXRX $1.36
- MYGN $6.43
- Resistance Level
- LXRX $1.52
- MYGN $6.89
- Average True Range (ATR)
- LXRX 0.13
- MYGN 0.48
- MACD
- LXRX -0.01
- MYGN 0.04
- Stochastic Oscillator
- LXRX 32.61
- MYGN 86.91
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.